Symbyax: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude housekeeping, em-dash to comma per style rule |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 15: | Line 15: | ||
| bioavailability = Olanzapine 60% (oral); fluoxetine high (oral)<ref name="symbyax-label" /> | | bioavailability = Olanzapine 60% (oral); fluoxetine high (oral)<ref name="symbyax-label" /> | ||
| pregnancy = Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.{{citation needed}} | | pregnancy = Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.{{citation needed}} | ||
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical- | | legal = [[USLegal:Prescription only|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly dementia patients<ref name="symbyax-label" /> | ||
| mechanism = <vote slug="symbyax-mech-claim">Olanzapine is a thienobenzodiazepine atypical neuroleptic with D2, 5-HT2A/2C, H1, M1, and α1 antagonism, providing both antimanic effect and adjunctive mood-stabilization. Fluoxetine is a selective serotonin reuptake inhibitor with antidepressant effect. The combination addresses the dual challenge of bipolar depression, risk of antidepressant-induced manic switch and inadequate response to mood stabilizer monotherapy, by pairing the fluoxetine antidepressant with the olanzapine mood-stabilizing/antimanic anchor.</vote> Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard<ref name="symbyax-label" />. | | mechanism = <vote slug="symbyax-mech-claim">Olanzapine is a thienobenzodiazepine atypical neuroleptic with D2, 5-HT2A/2C, H1, M1, and α1 antagonism, providing both antimanic effect and adjunctive mood-stabilization. Fluoxetine is a selective serotonin reuptake inhibitor with antidepressant effect. The combination addresses the dual challenge of bipolar depression, risk of antidepressant-induced manic switch and inadequate response to mood stabilizer monotherapy, by pairing the fluoxetine antidepressant with the olanzapine mood-stabilizing/antimanic anchor.</vote> Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard<ref name="symbyax-label" />. | ||
}} | }} | ||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:Neuroleptics]] | |||
[[Category:Antidepressants]] | |||
[[Category:Mood stabilizers]] | |||
[[Category:Fixed-dose combinations]] | |||